The adage "you get what you pay for" certainly is meaningful in the IP legal landscape. However, it is a challenge to get new, first-time inventors in the door to start discussing why they should retain an patent lawyer. With our co-branding options, we can help advance potential clientele through your pipeline. Become a co-branding partner and we will generate a promotional code to your potential clientele that will give them a discount on our services (10% savings). When they login, your logo will be co-branded with our software, a subtle reminder to the potential client.
Utilizing IP Street, you can search within technology classes to identify firms and patents anchored within a scope of inventions. Whether you are looking for inbound or outbound licensing opportunities, our search tools can help you Discover, Measure, Compare, Connect to, better business opportunities.
IP Street can assist you with questions regarding patent anayltics, patant intelligense, intellecutal proporty and the patant application. Our tools will assist you in writing patant cliams, exploring patant infrengment and understanding patant scoop. Interested in freedom 2 operate and patant valididy? IP Street will help you understand patent duration and all things intellectual property.
Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.